ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to establish the recommended dose of selumetinib, a novel MEK
inhibitor for use in combination with gemcitabine and cisplatin.